Abstract
Background
Aggressive fibromatosis (AF) comprises tumors with a varying biological behavior. Genetic tumor characteristics may be predictive of recurrence; hence, the prognostic value of three specific mutations on the CTNNB1 gene was evaluated in relation to known clinicopathologic risk factors in patients with primary, sporadic AF.
Methods
In a multi-institutional retrospective cohort study of patients with primary extra-abdominal and abdominal wall AF who underwent surgical treatment, the original pathology specimens were reviewed for the presence of a T41A, S45F, and 45P mutations on the CTNNB1 gene. For these mutations, the risk of recurrence was analyzed by the Kaplan–Meier method with log-rank test. Univariable and multivariable Cox regression was performed to calculate hazard ratios.
Results
A total of 101 patients were analyzed. During a median follow-up of 41 months, 17 recurrences were detected; the cumulative 5-year recurrence rate was 22.8 %. A specific CTNNB1 mutation was found in 76 patients, with the majority of patients having a T41A mutation (n = 49). CTNNB1 mutations were associated with the risk of recurrence: the presence of a S45F mutation was associated with a 5-year cumulative risk of recurrence of 63.8 % (P < 0.001). Multivariable analysis showed that young age and S45F mutation were independent risk factors (P = 0.011 and P < 0.001).
Conclusions
The presence of specific CTNNB1 mutations was predictive for recurrence in patients after surgical treatment for primary, sporadic extra-abdominal and abdominal AF. A S45F mutation increased the risk of recurrence significantly.
Similar content being viewed by others
References
Baumert BG, Spahr MO, Van Hochsetter A, et al. The impact of radiotherapy in the treatment of desmoid tumours. An international survey of 110 patients. A study of the Rare Cancer Network. Radiat Oncol. 2007;2:12.
Salas S, Dufresne A, Bui B, et al. Prognostic factors influencing progression-free survival determined from a series of sporadic desmoid tumors: a wait-and-see policy according to tumor presentation. J Clin Oncol. 2011;29:3553–3558.
Fiore M, Rimareix F, Mariani L, et al. Desmoid-type fibromatosis: a front-line conservative approach to select patients for surgical treatment. Ann Surg Oncol. 2009;16:2587–2593.
Tejpar S, Nollet F, Li C, et al. Predominance of beta-catenin mutations and beta-catenin dysregulation in sporadic aggressive fibromatosis (desmoid tumor). Oncogene. 1999;18:6615–6620.
Alman BA, Li C, Pajerski ME, Diaz-Cano S, Wolfe HJ. Increased beta-catenin protein and somatic APC mutations in sporadic aggressive fibromatoses (desmoid tumors). Am J Pathol. 1997;151:329–334.
Lips DJ, Barker N, Clevers H, Hennipman A. The role of APC and beta-catenin in the aetiology of aggressive fibromatosis (desmoid tumors). Eur J Surg Oncol. 2009;35:3–10.
Tejpar S, Michils G, Denys H, et al. Analysis of Wnt/Beta catenin signalling in desmoid tumors. Acta Gastroenterol Belg. 2005;68:5–9.
Miyoshi Y, Iwao K, Nawa G, Yoshikawa H, Ochi T, Nakamura Y. Frequent mutations in the beta-catenin gene in desmoid tumors from patients without familial adenomatous polyposis. Oncol Res. 1998;10:591–594.
Lazar AJ, Tuvin D, Hajibashi S, et al. Specific mutations in the beta-catenin gene (CTNNB1) correlate with local recurrence in sporadic desmoid tumors. Am J Pathol. 2008;173:1518–1527.
Dômont J, Salas S, Lacroix L, et al. High frequency of β-catenin heterozygous mutations in extra-abdominal fibromatosis: a potential molecular tool for disease management. Br J Cancer. 2010:102;1032–1036.
Colombo C, Miceli R, Lazar AJ, et al. CTNNB1 45F mutation is a molecular prognosticator of increased postoperative primary desmoid tumor recurrence: an independent, multicenter validation study. Cancer. 2013;119:3696–3702.
Mullen JT, DeLaney TF, Rosenberg AE, et al. Β-catenin mutation status and outcomes in sporadic desmoid tumors. Oncologist. 2013;18:1043–1049.
van Broekhoven DL, Verhoef C, Elias SG, et al. Local recurrence after surgery for primary extra-abdominal desmoid-type fibromatosis. Br J Surg. Aug. 2013;100:1214–1219.
Fletcher CDM, Unni KK, Mertens F, editors. World Health Organization classification of tumours. Pathology and genetics of tumours of soft tissue and bone. Lyon: IARC Press; 2002.
Crago AM, Denton B, Salas S, et al. A prognostic nomogram for prediction of recurrence in desmoid fibromatosis. Ann Surg. 2013;258:347–353.
Bo N, Wang D, Wu B, Chen L, Ruixue M. Analysis of beta-catenin expression and exon 3 mutations in pediatric sporadic aggressive fibromatosis. Pediatr Dev Pathol. 2012;15:173–178.
Huss S, Nehles J, Binot E, et al. beta-catenin (CTNNB1) mutations and clinicopathological features of mesenteric desmoid-type fibromatosis. Histopathology. 2013;62:294–304.
Gronchi A, Colombo C, Le Péchoux C, et al. Sporadic desmoid-type fibromatosis: a stepwise approach to a non-metastasising neoplams—a position paper from the Italian and the French Sarcoma Group. Ann Oncol. 2014;25:578–583.
Keus RB, Nout RA, Blay JY, et al. Results of a phase II pilot study of moderate dose radiotherapy for inoperable desmoid-type fibromatosis—EORTC 62991-22998. Ann Oncol. 2013 Oct;24:2672–2676.
Guadagnolo BA, Zagars GK, Ballo MT, et al. Long-term outcomes for desmoid tumors treated with radiation therapy. Int J Radiat Oncol Biol Phys. 2008;71:441–447.
Gluck I, Griffith KA, Biermann JS, Feng FY, Lucas DR, Ben-Josef E. Role of radiotherapy in the management of desmoid tumors. Int J Radiat Oncol Biol Phys. 2011;80:787–792.
Constatinidou A, Jones RL, Scurr M, et al. Advanced aggressive fibromatoses: effective palliation with chemotherapy. Acta Oncol. 2011;50:455–461.
Garbay D, Le Cesne A, Penel N, et al. Chemotherapy in patients with desmoid tumors: a study from the French Sarcoma Group (FSG). Ann Oncol. 2012;23:182–186.
Disclosure
The authors declare no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Additional information
A video of the presentation of the data in this article at the 67th Annual Society of Surgical Oncology Cancer Symposium is available at www.surgonc.org/vm.
Rights and permissions
About this article
Cite this article
van Broekhoven, D.L.M., Verhoef, C., Grünhagen, D.J. et al. Prognostic Value of CTNNB1 Gene Mutation in Primary Sporadic Aggressive Fibromatosis. Ann Surg Oncol 22, 1464–1470 (2015). https://doi.org/10.1245/s10434-014-4156-x
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1245/s10434-014-4156-x